Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the sale of all rights, title and interest to Navidea’s Lymphoseek product. The agreement covers all U.S. Food and Drug Administration (FDA)-approved, pending and future oncology diagnostic indications in North America, subject to certain limitations, as well as certain other related assets. Under the terms of the LOI, Navidea would receive $80 million at closing, with future consideration tied to annual sales of the Lymphoseek product and certain sales-based milestones. Total consideration to Navidea would be capped at $310 million.

Mayfair Diagnostics, a medical imaging clinic in Calgary, Alberta, is revealing its newest medical imaging clinic in Coventry Hills, which is being described as the clinic of the future because of the way it was designed.

August 30, 2016 — Calgary Scientific Inc. announced in mid-July that ResolutionMD medical imaging software is registered ...

August 30, 2016 — Franciscan Health Rensselaer, Rensselaer, Ind., purchased a new Carestream DRX-Excel Plus radiography ...

August 30, 2016 — Mission Health and GE Healthcare announced a novel, 10-year outcomes-based agreement that will help ...

Treatment with magnetic resonance imaging (MRI)-guided focused ultrasound significantly improves tremors and quality of life in patients with essential tremor (ET), according to a study published in the August 25 issue of the New England Journal of Medicine.